{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:11:28Z","timestamp":1790230288419,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.coph.2018.12.003","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T13:48:34Z","timestamp":1546436914000},"page":"7-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Current pharmaceutical developments in atopic dermatitis"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8088-7059","authenticated-orcid":false,"given":"Laurent","family":"Misery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-8209","authenticated-orcid":false,"given":"Flavien","family":"Huet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Gouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Deleuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2018.12.003_bib0005","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1468-3083.2012.04636.x","article-title":"Guidelines for treatment of atopic eczema (atopic dermatitis) (part II)","volume":"26","author":"Ring","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coph.2018.12.003_bib0010","series-title":"Atopic Dermatitis. The Epidemiology, Causes and Prevention of Atopic Eczema","year":"2000"},{"key":"10.1016\/j.coph.2018.12.003_bib0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555924447","article-title":"Diagnostic features of atopic dermatitis","volume":"92","author":"Hanifin","year":"1980","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coph.2018.12.003_bib0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2133.1994.tb08530.x","article-title":"The U.K. Working Party\u2019s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis","volume":"131","author":"Williams","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0025","first-page":"1","article-title":"The atopic eczema\/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated (\u2018extrinsic\u2019) and the nonallergic (\u2018intrinsic\u2019) AEDS","volume":"13","author":"W\u00fcthrich","year":"2003","journal-title":"J Invest Allergol Clin Immunol"},{"key":"10.1016\/j.coph.2018.12.003_bib0030","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s12016-011-8276-9","article-title":"What is intrinsic atopic dermatitis?","volume":"41","author":"Roguedas-Contios","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.coph.2018.12.003_sbref0035","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0040","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2340\/00015555-2940","article-title":"Patient burden is associated with alterations in quality of life in adult patients with atopic dermatitis","volume":"98","author":"Misery","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.coph.2018.12.003_bib0045","unstructured":"Misery L, S\u00e9n\u00e9schal J, Reguiai Z, Merhand S, H\u00e9as S, Huet F, Taieb C, Ezzedine K: The impact of atopic dermatitis on sexual health. J Eur Acad Dermatol Venereol (in press)."},{"key":"10.1016\/j.coph.2018.12.003_bib0050","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/0190-9622(93)70099-F","article-title":"Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample","volume":"28","author":"Schult-Larsen","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jdermsci.2017.11.015","article-title":"Reconstructed human epidermis for in vitro studies on atopic dermatitis: a review","volume":"89","author":"Huet","year":"2018","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.coph.2018.12.003_bib0060","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/jid.2011.342","article-title":"Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect","volume":"132","author":"Brown","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0065","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/jid.2011.393","article-title":"One remarkable molecule: filaggrin","volume":"132","author":"Brown","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0070","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1038\/jid.2012.246","article-title":"Structure and function of the stratum corneum extracellular matrix","volume":"132","author":"Elias","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0075","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1194\/jlr.P030338","article-title":"Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients","volume":"53","author":"Janssens","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.coph.2018.12.003_bib0080","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000484406","article-title":"Emerging therapeutic options in atopic dermatitis: systemic therapies","volume":"233","author":"Nygaard","year":"2017","journal-title":"Dermatology"},{"key":"10.1016\/j.coph.2018.12.003_bib0085","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2018.12.003_bib0090","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaci.2017.07.006","article-title":"Therapeutic pipeline for atopic dermatitis: end of the drought?","volume":"140","author":"Paller","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2018.12.003_bib0095","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jaci.2011.10.042","article-title":"IL-31 regulates differentiation and filaggrin expression in human organotypic skin models","volume":"129","author":"Cornelissen","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2018.12.003_bib0100","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jaci.2015.01.048","article-title":"IL-33 impacts on the skin barrier by downregulating the expression of filaggrin","volume":"135","author":"Seltmann","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2018.12.003_bib0105","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jaci.2014.11.015","article-title":"The translational revolution and use of biologics in patients with inflammatory skin diseases","volume":"135","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2018.12.003_sbref0110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.coph.2018.12.003_bib0115","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/B978-0-12-397925-4.00021-3","article-title":"TSLP expression induced via toll-like receptor pathways in human keratinocytes","volume":"535","author":"Takai","year":"2014","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.coph.2018.12.003_bib0120","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1038\/jid.2015.318","article-title":"TSLP directly interacts with skin-homing Th2 cells highly expressing its receptor to enhance IL-4 production in atopic dermatitis","volume":"135","author":"Tatsuno","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0125","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coph.2018.12.003_bib0130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12016-010-8225-z","article-title":"Atopic dermatitis and the nervous system","volume":"41","author":"Misery","year":"2011","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.coph.2018.12.003_bib0135","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/exd.12798","article-title":"Self-maintenance of neurogenic inflammation contributes to a vicious cycle in skin","volume":"24","author":"Gouin","year":"2015","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0140","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jid.2018.01.034","article-title":"Major role for TRPV1 and InsP3R in PAR-2-elicited inflammatory mediator production in differentiated human keratinocytes","volume":"138","author":"Gouin","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coi.2018.05.005","article-title":"Cytokine modulation of atopic itch","volume":"54","author":"Trier","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coph.2018.12.003_bib0150","article-title":"The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis","volume":"2","author":"Bao","year":"2013","journal-title":"JAKSTAT"},{"key":"10.1016\/j.coph.2018.12.003_sbref0155","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Thaci","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2018.12.003_bib0160","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.12.003_bib0165","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.12.003_bib0170","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2018.12.003_bib0175","unstructured":"Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, Moate R, van der Merwe R: Treatment of atopic dermatitis with tralokimumab, an anti-IL-13 mAb. J Allergy Clin Immunol (in press)."},{"key":"10.1016\/j.coph.2018.12.003_bib0180","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2500\/aap.2018.39.4149","article-title":"Meta-analysis of randomized controlled trials for the efficacy and safety of anti-interleukin-13 therapy with lebrikizumab in patients with uncontrolled asthma","volume":"39","author":"Liu","year":"2018","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.coph.2018.12.003_bib0185","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0190","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/exd.13236","article-title":"Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody","volume":"27","author":"Oyama","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0195","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_sbref0200","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.12.003_bib0205","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2018.12.003_bib0210","unstructured":"Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R, de la Pe\u00f1a A, Nunes FP, Janes J, Gamalo M et al.: Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol [Epub ahead of print]."},{"key":"10.1016\/j.coph.2018.12.003_bib0215","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O\u2019Shea","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.coph.2018.12.003_bib0220","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"73","author":"Levy","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0225","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jaci.2010.09.002","article-title":"Staphylococcus aureus membrane and diacylated lipopeptide induce thymic stromal lymphopoietin in keratinocytes through the Toll-like receptor 2-Toll-like receptor 6 pathway","volume":"126","author":"Vu","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2018.12.003_bib0230","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2018.12.003_bib0235","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/0091-6749(82)90008-2","article-title":"Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness","volume":"70","author":"Grewe","year":"1982","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2018.12.003_bib0240","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/0091-6749(93)90321-6","article-title":"Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis","volume":"91","author":"Chan","year":"1993","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coph.2018.12.003_bib0245","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jaad.2017.11.056","article-title":"Phosphodiesterase 4 inhibitors","volume":"78","author":"Zebda","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0250","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0255","first-page":"341","article-title":"A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis","volume":"11","author":"Volf","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0260","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/archdermatol.2012.812","article-title":"A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults","volume":"148","author":"Samrao","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0265","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1046\/j.1365-2133.2002.04803.x","article-title":"Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis","volume":"147","author":"Toyoda","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0270","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/sj.jid.5700942","article-title":"Possible roles of epidermal opioid systems in pruritus of atopic dermatitis","volume":"127","author":"Tominaga","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coph.2018.12.003_bib0275","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0022-3565(24)34907-9","article-title":"Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans","volume":"290","author":"Machelska","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.coph.2018.12.003_sbref0280","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/2046-4053-3-25","article-title":"No high level evidence to support the use of oral H1 antihistamines as monotherapy for eczema: a summary of a Cochrane systematic review","volume":"3","author":"van Zuuren","year":"2014","journal-title":"Syst Rev"},{"key":"10.1016\/j.coph.2018.12.003_bib0285","unstructured":"Werfel T, Layton G, Yeadon M, Whitlock L, Osterloh I, Jimenez P, Liu W, Lynch V, Asher A, Tsianakas A, Purkins L: Efficacy and safety of histamine H4 receptor antagonist ZPL-3893787 in atopic dermatitis. J Allergy Clin Immunol [Epub ahead of print]."}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218301127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218301127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:50:35Z","timestamp":1761461435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489218301127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":57,"alternative-id":["S1471489218301127"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2018.12.003","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current pharmaceutical developments in atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2018.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}